10-Q: FitLife Brands Reports Strong Q3 2024 Results Driven by Acquisitions and Margin Improvements

FitLife Brands saw a significant increase in revenue and net income in Q3 2024, primarily driven by recent acquisitions and improved gross margins.

Summary

• FitLife Brands reported a 15% increase in revenue for the third quarter of 2024, reaching $15.977 million, compared to $13.902 million in the same period last year.
• The company's net income for Q3 2024 was $2.126 million, a 25% increase from $1.696 million in Q3 2023.
• Gross profit for the quarter increased by 23% to $7.001 million, up from $5.696 million in the prior year.
• The company's gross margin improved to 43.8% in Q3 2024, compared to 41.0% in Q3 2023.
• For the nine months ended September 30, 2024, revenue increased by 26% to $49.456 million, compared to $39.401 million in the same period last year.
• Net income for the first nine months of 2024 was $6.914 million, an 81% increase from $3.816 million in the same period of 2023.
• The company's cash and restricted cash balance was $4.720 million as of September 30, 2024.
• The company had $14.250 million outstanding on term loans as of September 30, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, driven by strategic acquisitions and improved operational efficiency. While there are some challenges, the overall tone is optimistic and indicates a positive trajectory for the company.

Positives

• The acquisition of MusclePharm assets contributed significantly to revenue growth.
• Gross margins improved due to higher margins from MRC and Legacy FitLife brands.
• Advertising and marketing expenses decreased by 14% in Q3 2024 due to targeted efforts to rationalize spending.
• The company saw a substantial increase in net income for both the quarter and the nine-month period.
• The company is in compliance with all loan covenants.
• The company's online sales channel continues to be a strong performer.

Negatives

• Legacy FitLife revenue decreased by 6% in Q3 2024, driven by a decline in wholesale revenue.
• Selling, general, and administrative expenses increased by 39% in Q3 2024 due to higher personnel costs and professional fees.
• The company incurred non-recurring severance costs of $184 thousand.
• MusclePharm revenue decreased 8% sequentially from the second quarter of 2024 to the third quarter of 2024.

Risks

• The company's wholesale revenue continues to be challenged by declining customer counts in brick-and-mortar stores.
• The company is dependent on cash flow from operations and amounts available under the Line of Credit to satisfy its working capital requirements.
• Fluctuations in foreign currency exchange rates could materially affect financial results.
• The company's stock price is an important component of the fair value calculation for goodwill, and significant price fluctuations could lead to potential impairment in future periods.

Future Outlook

The company anticipates that cash derived from operations and existing cash reserves, along with available borrowings under the Line of Credit, will be sufficient to provide for the company's liquidity for the next twelve months.

Management Comments

• Management believes that contribution, as defined by the Company, is a particularly relevant performance metric since it incorporates the gross profit associated with a specific brand or collection of brands as well as the advertising and marketing expenditures associated with the same brand or brands.
• Management currently has no intention to raise additional working capital through the sale of equity or debt securities and believes that the cash flow from operations and available borrowings under the Line of Credit will provide sufficient capital necessary to operate the business over the next twelve months.

Industry Context

The company's performance reflects a broader trend in the nutritional supplement industry, where online sales are becoming increasingly important. The acquisitions of MRC and MusclePharm are strategic moves to diversify product offerings and expand market reach.

Comparison to Industry Standards

• FitLife Brands' gross margin of 43.8% in Q3 2024 is competitive with other companies in the nutritional supplement industry, such as Herbalife (HLF) which reported a gross margin of 77.5% in their most recent quarter, and Nu Skin Enterprises (NUS) which reported a gross margin of 72.9% in their most recent quarter. However, these companies have different business models and product mixes.
• The company's focus on online sales aligns with the industry trend of increasing e-commerce penetration. Companies like Amazon and iHerb are major players in the online supplement market.
• FitLife's acquisition strategy is similar to other companies in the industry that seek growth through mergers and acquisitions, such as Nestle's acquisition of The Bountiful Company.
• The company's debt levels are comparable to other companies in the industry that have used debt financing to fund acquisitions and growth initiatives.

Stakeholder Impact

• Shareholders will benefit from the increased profitability and revenue growth.
• Employees may see increased job security and potential for career advancement.
• Customers will have access to a wider range of products through the expanded brand portfolio.
• Suppliers may see increased demand for their products due to the company's growth.
• Creditors will be reassured by the company's improved financial performance and compliance with loan covenants.

Next Steps

• The company will continue to focus on driving revenue growth through targeted investments in advertising and promotion.
• The company will explore additional new product launches.
• The company will continue discussions with potential new wholesale partners.
• The company will perform its next goodwill impairment analysis in December 2024.

Key Dates

Keywords

nutritional supplements, wellness products, acquisitions, revenue growth, gross margin, net income, online sales, wholesale, FitLife Brands, MusclePharm, Mimis Rock Corp, FTLF